Prognostic factors in the so-called malignant mesenchymoma: A clinicopathological and immunohistochemical analysis

Oncology Reports

Volumn 10, Issue 4, 2003, Pages 803-811

  Adachi, Toshisada ^a,c   Yoshinao, O D A ^a   Sakamoto, Akio ^a   Terashi, Takahiro ^a   Tamiya, Sadafumi ^a   Hachitanda, Yoichi ^b   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Chondrosarcoma; Dedifferentiation; Leiomyosarcoma; Liposarcoma; Malignant mesenchymoma; mdm2; MIB 1; Osteosarcoma; p53; Prognostic indicators; Rhabdomyosarcoma

Indexed keywords

KI 67 ANTIGEN; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; MALE; MESENCHYMOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SOFT TISSUE TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MALE; MESENCHYMOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1542787694     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.4.803     Document Type: Article

References (30)

1. Stout AP: Mesenchymoma, the mixed tumor of mesenchymal derivatives. Ann Surg 127: 278-290, 1948.
2. Weiss SW and Goldblum JR (eds): Enzinger and Weiss's Soft Tissue Tumors. 4th edition. Mosby, St. Louis, 2001.
3. Kempson RL, Fletcher CDM, Evans HL, Hendrickson MR and Sibley RK: Tumors of the soft tissues. Atlas of Tumor Pathology. 3rd series. Fascicle 30. Armed Forces Institute of Pathology, Washington, DC, 2001.
4. Kessler S, Mirra JM, Ishii T, Thompson JC and Brien EW: Primary malignant mesenchymoma of bone: case report, literature review, and distinction of this entity from mesenchymal and dedifferentiated chondrosarcoma. Skeletal Radiol 24: 291-295, 1995.
5. Coindre JM, Trojani M, Contesso G, et al: Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58: 306-309, 1986. (Pubitemid 16058606)
6. Enzinger FM and Weiss SW (eds): Malignant mesenchymoma. In: Soft Tissue Tumors. 3rd edition. Mosby, St. Louis, pp1087-1089, 1995.
7. Enzinger FM and Weiss SW (eds): Malignant mesenchymoma. In: Soft Tissue Tumors. 2nd edition. Mosby, St. Louis, pp958-960, 1988.
8. Kikuchi S, Asai M, Horiuchi Y, et al: A case of malignant mesenchymoma of the maxilla. Gan No Rinsho-Jpn J Cancer Clin (in Japanese) 36: 621-628, 1990.
9. Brady MS, Perino G, Tallini G, Russo P and Woodruff JM: Malignant mesenchymoma. Cancer 77: 467-473, 1996. (Pubitemid 26047567)
10. Newman PL and Fletcher CD: Malignant mesenchymoma. Clinicopathologic analysis of a series with evidence of low-grade behaviour. Am J Surg Pathol 15: 607-614, 1991.
11. Tallini G, Erlandson RA, Brennan MF and Woodruff JM: Divergent myosarcomatous differentiation in retroperitoneal liposarcoma. Am J Surg Pathol 17: 546-556, 1993. (Pubitemid 23152592)
12. Evans HL, Khurana KK, Kemp BL and Ayala AG: Heterologous elements in the dedifferentiated component of dedifferentiated liposarcoma. Am J Surg Pathol 18: 1150-1157, 1994. (Pubitemid 24337622)
13. Geurts van Kessel A, Simons A, Comtesse PP, et al: Ring chromosomes in a malignant mesenchymoma. Cancer Genet Cytogenet 109: 119-122, 1999. (Pubitemid 29128351)
14. Folpe AL and Weiss SW: Lipoleiomyosarcoma (well-differentiated liposarcoma with leiomyosarcomatous differentiation). A clinicopathologic study of nine cases including one with dedifferentiation. Am J Surg Pathol 26: 742-749, 2002. (Pubitemid 34546939)
15. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994. (Pubitemid 24289415)
16. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 Mutations in human cancers. Science 253: 49-53, 1991. (Pubitemid 21917115)
17. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991. (Pubitemid 21896613)
18. Cordon-Cardo C, Latres E, Drobnjak M, et al: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799, 1994. (Pubitemid 24068339)
19. Leach FS, Tokino T, Meltzer P, et al: p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53 (Suppl.): 2231-2234, 1993. (Pubitemid 23156805)
20. Ciechanover A, DiGiuseppe JA, Bercovich B, et al: Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA 88: 139-143, 1991. (Pubitemid 21914443)
21. Reich NC, Oren M and Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 3: 2143-2150, 1983.
22. Kohler MF, Berchuck A, Davidoff AM, et al: Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52: 1622-1627, 1992.
23. Latres E, Drobnjak M, Pollack D, et al: Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 145: 345-355, 1994. (Pubitemid 24245835)
24. Marchetti A, Buttitta F, Pellegrini S, et al: mdm2 Gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4: 93-97, 1995.
25. WAF1in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. Int J Surg Pathol 9: 99-109, 2001.
26. Miyajima K, Tamiya S, Oda Y, et al: Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma: real-time semi-quantitative reverse transcription-polymerase chain reaction. Cancer Lett 164: 177-188, 2001. (Pubitemid 32155506)
27. Oda Y, Miyajima K, Kawaguchi K, et al: Pleomorphic leiomyosarcoma:. clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma. Am J Surg Pathol 25: 1030-1038, 2001. (Pubitemid 32685900)
28. Ayan I, Dogan O, Kebudi R, et al: Immunohistochemical detection of p53 protein in rhabdomyosarcoma: association with clinicopathological features and outcome. J Pediatr Hematol Oncol 19: 48-53, 1997. (Pubitemid 27124058)
29. Nawa G, Ueda T, Mori S, et al: Prognostic significance of Ki67 (MIB1) proliferation index and p53 over-expression in chondrosarcomas. Int J Cancer 69: 86-91, 1996. (Pubitemid 26164860)
30. Feugeas O, Guriec N, Babin-Boilletot A, et al: Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14: 467-472, 1996. (Pubitemid 26051009)